Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
Adult Anaplastic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We here report neuroimaging findings in a 69-year-old man with a "butterfly" pattern on dynamic FET [O-(2-[F]-fluoroethyl)-L-tyrosine] PET and the diagnosis of an anaplastic astrocytoma (WHO grade III; IDH-1/-2 wildtype, no 1p/19q co-deletion) but without typical MRI contrast enhancement.
|
31348085 |
2019 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
33-year-old nulligravid woman with newly diagnosed anaplastic astrocytoma (AA; WHO grade III, IDH1-negative) sought fertility preservation.
|
29739361 |
2018 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis demonstrated that T2-EOR (HR 3.28; 95% CI 1.22-8.81; p = 0.0192) and IDH1 mutation (HR 3.90; 95% CI 1.53-10.75; p = 0.0044) were predictive of survival in patients with AA and AOA.
|
28885120 |
2018 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The histopathologic examination confirmed a leptomeningeal spread of a K27M-mutated anaplastic astrocytoma (WHO° III) without R132H-IDH1 mutation.
|
29066318 |
2018 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma.
|
30203362 |
2018 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status.
|
28110298 |
2017 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3).
|
28851427 |
2017 |
Adult Anaplastic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors.
|
28640702 |
2017 |
Adult Anaplastic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma.
|
26443480 |
2016 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A second surgery was performed, and pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma.
|
26911558 |
2016 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The JHH-273 model is characteristic of anaplastic astrocytoma and represents a valuable tool for investigating the pathogenesis of this distinct molecular subset of gliomas and for preclinical testing of compounds targeting IDH1 mutations or alternative lengthening of telomeres.
|
25471051 |
2015 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We show that expression levels of many proteins are altered in IDH1(R132H) mutant anaplastic astrocytoma.
|
24473683 |
2014 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To characterize the contribution of wild-type IDH1 to cancer cell D-2HG production, we established an IDH1-mutated astrocytoma (IMA) cell line from a WHO grade III anaplastic astrocytoma.
|
23204232 |
2013 |
Adult Anaplastic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalences of mutations of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A), the glioma cytosine-phosphate-guanine island methylator phenotype (G-CIMP), and methylation of alkylpurine DNA N-glycosylase (APNG) and peroxiredoxin 1 (PRDX1) promoters were determined in a representative biomarker subset (n = 126 patients with anaplastic astrocytoma or glioblastoma) from the NOA-08 trial.
|
23595628 |
2013 |
Adult Anaplastic Astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report the generation of an endogenous IDH1 anaplastic astrocytoma model which rapidly grows in vivo, produces 2-HG and exhibits DNA hypermethylation.
|
24077805 |
2013 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To validate mutation frequency, IDH1 gene at codon 132 was sequenced in 74 diffusely infiltrating astrocytomas: diffuse astrocytoma (DA; World Health Organization [WHO] grade II), anaplastic astrocytoma (AA; WHO grade III), and GBM (WHO grade IV).
|
22904127 |
2012 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The lack of expression of GFAP or MAP-2 raised the question of a secondary malignancy, however, molecular genetic analysis of IDH1 and p53 revealed the same mutations in the anaplastic astrocytoma from 2006 as in the sarcomatoid tumor operated in 2010.
|
21955926 |
2011 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
|
21088844 |
2010 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations were frequent in low-grade diffuse astrocytomas (88%) and in secondary glioblastomas that developed through progression from low-grade diffuse or anaplastic astrocytoma (82%).
|
19246647 |
2009 |
Adult Anaplastic Astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To establish the frequency of IDH1 mutations in glioblastomas at a population level, and to assess whether they allow reliable discrimination between primary (de novo) glioblastomas and secondary glioblastomas that progressed from low-grade or anaplastic astrocytoma.
|
19755387 |
2009 |